Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophrenia

被引：0
|
作者：
Dominic Pilon
Erik Muser
Patrick Lefebvre
Rhiannon Kamstra
Bruno Emond
Kruti Joshi
机构：
[1] Groupe d’analyse,
[2] Ltée,undefined
[3] Janssen Scientific Affairs,undefined
[4] LLC,undefined
来源：
BMC Psychiatry | / 17卷
关键词：
Oral Atypical Antipsychotics (OAA); Healthcare Resource Utilization; Mean Monthly Cost; Medical Cost Savings; Higher Pharmacy Costs;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Population Pharmacokinetics of Intramuscular Paliperidone Palmitate in Patients with Schizophrenia A Novel Once-Monthly, Long-Acting Formulation of an Atypical Antipsychotic
    Samtani, Mahesh N.
    Vermeulen, An
    Stuyckens, Kim
    CLINICAL PHARMACOKINETICS, 2009, 48 (09) : 585 - 600
  • [32] Once-monthly injection of paliperidone palmitate in patients with recently diagnosed and chronic schizophrenia: a post-hoc comparison of efficacy and safety
    Si, Tianmei
    Zhuo, Jianmin
    Turkoz, Ibrahim
    Mathews, Maju
    Tan, Wilson
    Feng, Yu
    EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (17) : 1799 - 1809
  • [33] A comparison of treatment patterns, healthcare resource utilization, and costs among young adult Medicaid beneficiaries with schizophrenia treated with paliperidone palmitate or oral atypical antipsychotics in the US
    Manjelievskaia, Janna
    Amos, Tony B.
    El Khoury, Antoine C.
    Vlahiotis, Anna
    Cole, Ashley
    Juneau, Paul
    JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (12) : 1221 - 1229
  • [34] The Impact of Once-Monthly Paliperidone Palmitate on Healthcare Utilization Among Patients With Schizophrenia Treated in an Integrated Healthcare System: A Retrospective Mirror-Image Study
    Mahabaleshwarkar, Rohan
    Lin, Dee
    Fishman, Jesse
    Blair, Todd
    Hetherington, Timothy
    Palmer, Pooja
    Patel, Charmi
    Benson, Carmela
    Joshi, Kruti
    Krull, Constance
    Tcheremissine, Oleg V.
    ADVANCES IN THERAPY, 2021, 38 (04) : 1958 - 1974
  • [35] The Impact of Once-Monthly Paliperidone Palmitate on Healthcare Utilization Among Patients With Schizophrenia Treated in an Integrated Healthcare System: A Retrospective Mirror-Image Study
    Rohan Mahabaleshwarkar
    Dee Lin
    Jesse Fishman
    Todd Blair
    Timothy Hetherington
    Pooja Palmer
    Charmi Patel
    Carmela Benson
    Kruti Joshi
    Constance Krull
    Oleg V. Tcheremissine
    Advances in Therapy, 2021, 38 : 1958 - 1974
  • [36] Design and Rationale of the Paliperidone Palmitate Research in Demonstrating Effectiveness (PRIDE) Study: A Novel Comparative Trial of Once-Monthly Paliperidone Palmitate Versus Daily Oral Antipsychotic Treatment for Delaying Time to Treatment Failure in Persons With Schizophrenia
    Alphs, Larry
    Mao, Lian
    Rodriguez, Stephen C.
    Hulihan, Joe
    Starr, H. Lynn
    JOURNAL OF CLINICAL PSYCHIATRY, 2014, 75 (12) : 1388 - 1393
  • [37] Impact of once-monthly paliperidone palmitate treatment on hospitalisation risk in patients with schizophrenia switching from oral antipsychotics
    Li, N.
    Zhuo, J.
    Tan, W.
    Turkoz, I.
    Mathews, M.
    Feng, Y.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 : S941 - S941
  • [38] Once-monthly paliperidone palmitate versus daily oral antipsychotics delays adverse real-world consequences of schizophrenia
    Starr, H.
    Mao, L.
    Rodriguez, S.
    Alphs, L.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2014, 24 : S550 - S551
  • [39] Tolerability of initiation doses of once-monthly paliperidone palmitate in patients with recently diagnosed schizophrenia in an acute treatment trial (vol 1,pg 111, 2011)
    Bossie, Cynthia A.
    Fu, Dong-Jing
    Sliwa, Jennifer Kern
    Ma, Yi-Wen
    Alphs, Larry
    THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY, 2011, 1 (05) : 163 - 163
  • [40] Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional study
    Schreiner, Andreas
    Caspi, Asaf
    Bergmans, Paul
    Cherubin, Pierre
    Keim, Sofia
    Lara, Elsa
    Pinchuk, Irina
    Schuepbach, Daniel
    Suleman, Sajid
    Hargarter, Ludger
    PSYCHOPHARMACOLOGY, 2017, 234 (01) : 3 - 13
12345